Apeloa Pharmaceutical Co

Apeloa Pharmaceutical Co Liabilities

The The Liabilities of Apeloa Pharmaceutical Co (000739.SZ) as of Oct 21, 2026 is 5.97 B CNY. In the previous year, The Liabilities was 5.98 B CNY — a change of -0.12% (lower).

Liabilities

5.97 BCNY

YoY

-0.12%

Last updated:

In 2025, Apeloa Pharmaceutical Co's total liabilities amounted to 5.97 B CNY, a -0.12% difference from the 5.98 B CNY total liabilities in the previous year.

The Apeloa Pharmaceutical Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
2.41 B CNY
Jan 1, 2019
2.75 B CNY
Jan 1, 2020
3.10 B CNY
Jan 1, 2021
3.98 B CNY
Jan 1, 2022
6.50 B CNY
Jan 1, 2023
6.54 B CNY
Jan 1, 2024
5.98 B CNY
Jan 1, 2025
5.97 B CNY
The Apeloa Pharmaceutical Co Liabilities history
YEARLiabilitiesYoY
5.97 BCNY-0.12%
5.98 BCNY-8.54%
6.54 BCNY+0.54%
6.50 BCNY+63.18%
3.98 BCNY+28.37%
3.10 BCNY+12.69%
2.75 BCNY+14.46%
2.41 BCNY-8.88%
2.64 BCNY-12.03%
3.00 BCNY+0.82%
2.98 BCNY+8.07%
2.76 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Apeloa Pharmaceutical Co Stock analysis

What does Apeloa Pharmaceutical Co do? Apeloa Pharmaceutical Co., Ltd. generates revenue through the research, development, and production of active pharmaceutical ingredient (API) intermediates, contract development and production services (CDMO), and preparations. The company’s main products include bulk drugs, intermediates, chemical preparations, and Chinese traditional medicine preparations such as ubenimex capsules, cefixime, and amantadine. These products are sold to both domestic and overseas markets, with the company distributing its offerings across these segments. The firm’s business model focuses on serving pharmaceutical manufacturers and healthcare providers through its comprehensive range of API intermediates and finished preparations. The company’s revenue streams are derived from the sale of bulk drugs, intermediates, and chemical preparations, alongside its Chinese traditional medicine preparations like ubenimex capsules and cefixime. These products are targeted at pharmaceutical manufacturers seeking API intermediates and finished drug formulations. Apeloa Pharmaceutical serves both domestic and international clients, with its products distributed in both markets. The company’s CDMO services further support clients in the development and production of pharmaceutical products. Apeloa Pharmaceutical’s core business involves the production and sale of API intermediates, bulk drugs, and various preparations, including traditional Chinese medicine products. The company’s main customers are pharmaceutical manufacturers and healthcare providers who require intermediates for drug manufacturing and finished preparations for market distribution. Its domestic and overseas market presence ensures a diversified revenue base, with products like ubenimex capsules and amantadine contributing to its product portfolio. Apeloa Pharmaceutical Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Apeloa Pharmaceutical Co's Liabilities

Apeloa Pharmaceutical Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Apeloa Pharmaceutical Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Apeloa Pharmaceutical Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Apeloa Pharmaceutical Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Apeloa Pharmaceutical Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Apeloa Pharmaceutical Co stock

The Liabilities of Apeloa Pharmaceutical Co is 5.97 B CNY in 2025.

The Liabilities of Apeloa Pharmaceutical Co changed from 5.98 B CNY to 5.97 B CNY, representing a -0.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Apeloa Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Apeloa Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Apeloa Pharmaceutical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Apeloa Pharmaceutical Co